Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Current Leases for 7 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 20.0% to $12.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.0 million, a 20.0% increase, with the full-year FY2025 number at $12.0 million, up 20.0% from a year prior.
  • Current Leases was $12.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $12.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $12.8 million in Q1 2024 to a low of $9.4 million in Q1 2021.
  • A 5-year average of $11.3 million and a median of $11.5 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 37.42% in 2021, then decreased 20.6% in 2024.
  • Ultragenyx Pharmaceutical's Current Leases stood at $11.1 million in 2021, then grew by 6.44% to $11.8 million in 2022, then increased by 6.93% to $12.6 million in 2023, then fell by 20.6% to $10.0 million in 2024, then rose by 20.0% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Current Leases are $12.0 million (Q4 2025), $12.1 million (Q3 2025), and $11.8 million (Q2 2025).